SCHEMBL1463540

SCHEMBL1463540

O=C(Nc1cccc(Br)c1)Nc1ccc(Br)cc1-c1nnn[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 6/20 0.50
TRPV1 Q8NER1 1/20 0.47
STING1 Q86WV6 1/20 0.47
LMNA P02545 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HTT P42858 2/20 0.46
MAPT P10636 1/20 0.46
GRIK2 Q13002 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 2/20 0.44
ALOX15 P16050 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDR P35968 3/20 0.44
PDGFRA P16234 1/20 0.44
KIT P10721 2/20 0.43
FLT3 P36888 2/20 0.43
GRM5 P41594 1/20 0.43
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1463359 0.91 KMT2A (0.58) GRIK1TRPV1LMNAMEN1KMT2A
SCHEMBL1462286 0.91 SMN1; SMN2 (0.54) GRIK1TRPV1LMNAMEN1KMT2A
SCHEMBL1463226 0.91 MEN1 (0.47) GRIK1TRPV1LMNAMEN1KMT2A
SCHEMBL1463081 0.90 MEN1 (0.47) GRIK1TRPV1LMNAMEN1KMT2A
SCHEMBL1463512 0.90 MGLL (0.50) GRIK1STING1LMNAMEN1KMT2A
SCHEMBL1463507 0.89 KMT2A (0.45) GRIK1STING1LMNAMEN1KMT2A
SCHEMBL1462393 0.88 GRIK1 (0.60) GRIK1TRPV1MEN1KMT2AHTT
SCHEMBL1462414 0.88 RAB9A (0.54) TRPV1MEN1KMT2AHTTMAPT
SCHEMBL1463246 0.88 KMT2A (0.53) TRPV1MEN1KMT2AHTTMAPT
SCHEMBL4025085 0.87 MEN1 (0.60) GRIK1LMNAMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP claimed
US-20070293553-A1 Diphenylurea Derivatives Useful As Potassium Channel Activators NEUROSEARCH A/S (DK) 2007-12-20 US claimed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US claimed
CN-1845726-A Erg channel openers for the treatment of cardiac arrhythmias POSEIDON PHARMACEUTICALS AS (DK) 2006-10-11 CN claimed
EP-1663192-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS Poseidon Pharmaceuticals A/S (DK) 2006-06-07 EP claimed
WO-2005023238-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
WO-2005023237-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
CN-1118462-C Substituted phenyl derivatives, their preparation and use NEUROSEARCH AS (DK) 2003-08-20 CN claimed
CN-1253553-A Substituted phenyl derivatives, their preparation and use NEUROSEARCH AS (DK) 2000-05-17 CN claimed
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS OLESEN SOEREN PETER 2011-03-24 US disclosed
US-7851492-B2 ERG channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2010-12-14 US disclosed
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP disclosed
US-20070293553-A1 Diphenylurea Derivatives Useful As Potassium Channel Activators NEUROSEARCH A/S (DK) 2007-12-20 US disclosed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US disclosed
CN-1845726-A Erg channel openers for the treatment of cardiac arrhythmias POSEIDON PHARMACEUTICALS AS (DK) 2006-10-11 CN disclosed
CN-1118462-C Substituted phenyl derivatives, their preparation and use NEUROSEARCH AS (DK) 2003-08-20 CN disclosed
CN-1253553-A Substituted phenyl derivatives, their preparation and use NEUROSEARCH AS (DK) 2000-05-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias KCNJ2, KCNN3, KCNE1 GRIK1 622/4885TRPV1 88/4885STING1 3197/4885
US-20070293553-A1 Diphenylurea Derivatives Useful As Potassium Channel Activators KCNJ2, KCNH2, KCNH3 GRIK1 216/4885TRPV1 41/4885STING1 4510/4885
US-20110071164-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS KCNJ2, KCNN3, KCNE1 GRIK1 622/4885TRPV1 88/4885STING1 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.